Novoeight (Turoctocog Alfa)

Turoctocog alfa, the active ingredient in Novoeight, is a recombinant factor VIII presented as a solution for injection for intravenous use. It restores the intrinsic pathway of coagulation in patients with congenital factor VIII deficiency, providing prophylactic and on‑demand treatment for hemophilia A. Novoeight is marketed in the European Union and complies with EU regulatory standards.

GNH USA supplies Novoeight as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Novoeight is a recombinant factor VIII used to manage hemophilia A by replacing deficient clotting factor VIII.

- Hemophilia A (congenital factor VIII deficiency): prophylaxis to maintain protective factor levels and reduce spontaneous bleeds. - Hemophilia A: on‑demand treatment of bleeding episodes to achieve rapid haemostasis. - Hemophilia A: peri‑operative management to control surgical or invasive‑procedure related bleeding.

Novoeight may be associated with adverse reactions following intravenous administration.

Common Side Effects: - Injection site pain or erythema. - Headache. - Fever. - Nausea. - Arthralgia. - Fatigue.

Serious or Rare Side Effects: - Development of neutralizing antibodies (inhibitors) against factor VIII. - Anaphylactic or severe allergic reactions. - Thromboembolic events. - Hemolysis. - Severe systemic allergic response.

Novoeight requires careful clinical monitoring and adherence to handling guidelines.

- Monitor inhibitor development: regularly test for anti‑factor VIII antibodies. - Assess bleeding risk before surgery: coordinate peri‑operative dosing. - Adjust dose based on pharmacokinetic monitoring and clinical response. - Avoid use in patients with known hypersensitivity to any component of the formulation. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Novoeight may interact with other agents affecting haemostasis or immune response.

Major Interactions (Avoid): - Concurrent use of other recombinant factor VIII products may increase inhibitor risk. - Simultaneous administration with high‑dose activated prothrombin complex concentrates can raise thrombosis risk. - Use with investigational gene‑therapy vectors targeting factor VIII without monitoring may cause unpredictable coagulation effects.

Moderate Interactions (Monitor Closely): - Co‑administration with anticoagulants (e.g., warfarin) may require dose adjustments. - Use with aspirin or NSAIDs may exacerbate bleeding tendencies. - Concomitant desmopressin may alter endogenous factor VIII levels. - Interaction with immunosuppressive agents may affect inhibitor development. - Use with certain antibiotics (e.g., quinolones) may increase infusion‑related reactions.